Janus Kinase 1

Newly released data from the phase 3 STOP-HS clinical trial program reveal positive results in hidradenitis suppurativa from povorcitinib treatment, Incyte announced in a press release.

Based on the pathogenesis of eosinophilic cellulitis, treatment targeting Janus kinase 1 and 2 should be developed to treat this disease, according to a study.

NEW ORLEANS — Phase 2 clinical trial results confirmed the benefit of upadacitinib, a selective Janus kinase 1 inhibitor, in the treatment of hidradenitis suppurativa, according to a presentation here.

Rinvoq, an oral selective Janus kinase 1 inhibitor, helped induce endoscopic remission in patients with moderate-to-severe Crohn’s disease, according to study results.

Ruxolitinib induced responses in about one-third of a cohort of patients with chronic neutrophilic leukemia and atypical chronic myeloid leukemia, according to results of a single-arm phase 2 study published in Journal of Clinical Oncology.

Researchers have identified a minimally invasive technique using tape strips to study the phenotype and specific biomarkers in children with atopic dermatitis, in a popular story at Healio Dermatology, just in time for National Eczema Awareness Month.